{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:15:59Z","timestamp":1790054159129,"version":"4.0.1"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T00:00:00Z","timestamp":1535414400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T00:00:00Z","timestamp":1535414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000957","name":"Alzheimer\u2019s Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005572","name":"Duke Institute for Brain Sciences, Duke University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005572","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001694","name":"International Retinal Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006510","name":"Duke University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Avid\/Lilly"},{"name":"Anthrotonix"},{"name":"Muses Labs"},{"DOI":"10.13039\/100011338","name":"AstraZeneca Schweiz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011338","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015254","name":"Cognoptix","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015254","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Lundbeck\/Takeda"},{"name":"Piramal"},{"name":"Genomind"},{"name":"Sonexa"},{"name":"Targacept"},{"name":"NeuroPro"},{"name":"Neurocog Trials"},{"name":"Forum"},{"name":"Holmusk"},{"name":"T3D Therapeutics"},{"DOI":"10.13039\/501100003037","name":"Elan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003037","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Avanir"},{"name":"Neuronetrix"},{"DOI":"10.13039\/100002565","name":"Alzheimer\u2019s Drug Discovery Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ADCS\/UCSD"},{"name":"Hintsa Performance"},{"name":"Crossings"},{"name":"Physicians Postgraduate Press"},{"name":"Maxwell Health"},{"name":"Evidation"},{"name":"Adverse Events Inc"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"World Economic Forum"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00415-018-9028-z","type":"journal-article","created":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T14:17:42Z","timestamp":1535465862000},"page":"1566-1577","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Ocular amyloid imaging at the crossroad of Alzheimer\u2019s disease and age-related macular degeneration: implications for diagnosis and therapy"],"prefix":"10.1007","volume":"266","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3599-9021","authenticated-orcid":false,"given":"Sally S.","family":"Ong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Proia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather E.","family":"Whitson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Farsiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Murali","family":"Doraiswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora M.","family":"Lad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,28]]},"reference":[{"key":"9028_CR1","unstructured":"GBD2016 (2017) Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet (accessed)"},{"issue":"2","key":"9028_CR2","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X et al (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2(2):e106\u2013e116","journal-title":"Lancet Glob Health"},{"issue":"Suppl 1","key":"9028_CR3","doi-asserted-by":"publisher","first-page":"S204","DOI":"10.1016\/j.neuroimage.2010.06.020","volume":"54","author":"M Koronyo-Hamaoui","year":"2011","unstructured":"Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV et al (2011) Identification of amyloid plaques in retinas from Alzheimer\u2019s patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage 54(Suppl 1):S204\u2013S217","journal-title":"Neuroimage"},{"issue":"11","key":"9028_CR4","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.1167\/iovs.08-1849","volume":"49","author":"A Ning","year":"2008","unstructured":"Ning A, Cui J, To E, Ashe KH, Matsubara J (2008) Amyloid-beta deposits lead to retinal degeneration in a mouse model of Alzheimer disease. Invest Ophthalmol Vis Sci 49(11):5136\u20135143","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"9028_CR5","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.exer.2014.08.006","volume":"127","author":"MM Edwards","year":"2014","unstructured":"Edwards MM, Rodriguez JJ, Gutierrez-Lanza R, Yates J, Verkhratsky A, Lutty GA (2014) Retinal macroglia changes in a triple transgenic mouse model of Alzheimer\u2019s disease. Exp Eye Res 127:252\u2013260","journal-title":"Exp Eye Res"},{"issue":"7","key":"9028_CR6","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/j.neurobiolaging.2013.01.006","volume":"34","author":"PA Williams","year":"2013","unstructured":"Williams PA, Thirgood RA, Oliphant H et al (2013) Retinal ganglion cell dendritic degeneration in a mouse model of Alzheimer\u2019s disease. Neurobiol Aging 34(7):1799\u20131806","journal-title":"Neurobiol Aging"},{"issue":"5","key":"9028_CR7","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.2353\/ajpath.2009.090159","volume":"175","author":"B Liu","year":"2009","unstructured":"Liu B, Rasool S, Yang Z et al (2009) Amyloid-peptide vaccinations reduce {beta}-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer\u2019s transgenic mice. Am J Pathol 175(5):2099\u20132110","journal-title":"Am J Pathol"},{"issue":"2","key":"9028_CR8","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1167\/iovs.08-2384","volume":"50","author":"SE Perez","year":"2009","unstructured":"Perez SE, Lumayag S, Kovacs B, Mufson EJ, Xu S (2009) Beta-amyloid deposition and functional impairment in the retina of the APPswe\/PS1DeltaE9 transgenic mouse model of Alzheimer\u2019s disease. Invest Ophthalmol Vis Sci 50(2):793\u2013800","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"9028_CR9","doi-asserted-by":"publisher","first-page":"e0135499","DOI":"10.1371\/journal.pone.0135499","volume":"10","author":"LY Du","year":"2015","unstructured":"Du LY, Chang LY, Ardiles AO et al (2015) Alzheimer\u2019s Disease-Related Protein Expression in the Retina of Octodon degus. PLoS One 10(8):e0135499","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"9028_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1601-183X.2007.00374.x","volume":"7","author":"C Le Cudennec","year":"2008","unstructured":"Le Cudennec C, Faure A, Ly M, Delatour B (2008) One-year longitudinal evaluation of sensorimotor functions in APP751SL transgenic mice. Genes Brain Behav 7(Suppl 1):83\u201391","journal-title":"Genes Brain Behav"},{"issue":"4","key":"9028_CR11","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1037\/0735-7044.119.4.884","volume":"119","author":"G Hale","year":"2005","unstructured":"Hale G, Good M (2005) Impaired visuospatial recognition memory but normal object novelty detection and relative familiarity judgments in adult mice expressing the APPswe Alzheimer\u2019s disease mutation. Behav Neurosci 119(4):884\u2013891","journal-title":"Behav Neurosci"},{"key":"9028_CR12","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.neulet.2016.04.059","volume":"623","author":"VK Gupta","year":"2016","unstructured":"Gupta VK, Chitranshi N, Gupta VB et al (2016) Amyloid beta accumulation and inner retinal degenerative changes in Alzheimer\u2019s disease transgenic mouse. Neurosci Lett 623:52\u201356","journal-title":"Neurosci Lett"},{"issue":"1","key":"9028_CR13","first-page":"24","volume":"36","author":"KU Loffler","year":"1995","unstructured":"Loffler KU, Edward DP, Tso MOM (1995) Immunoreactivity against tau, amyloid precursor protein, and beta-amyloid in the human retina. Invest Ophthal 36(1):24\u201331","journal-title":"Invest Ophthal"},{"issue":"1","key":"9028_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/ana.24548","volume":"79","author":"C La Morgia","year":"2016","unstructured":"La Morgia C, Ross-Cisneros FN, Koronyo Y et al (2016) Melanopsin retinal ganglion cell loss in Alzheimer disease. Ann Neurol 79(1):90\u2013109","journal-title":"Ann Neurol"},{"key":"9028_CR15","doi-asserted-by":"crossref","unstructured":"Koronyo Y, Biggs D, Barron E et al. Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer\u2019s disease. JCI Insight 2017; 2(16)","DOI":"10.1172\/jci.insight.93621"},{"issue":"1","key":"9028_CR16","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1167\/iovs.13-12888","volume":"55","author":"Y Tsai","year":"2014","unstructured":"Tsai Y, Lu B, Ljubimov AV et al (2014) Ocular changes in TgF344-AD rat model of Alzheimer\u2019s disease. Invest Ophthalmol Vis Sci 55(1):523\u2013534","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"9028_CR17","doi-asserted-by":"publisher","first-page":"e53547","DOI":"10.1371\/journal.pone.0053547","volume":"7","author":"C Schon","year":"2012","unstructured":"Schon C, Hoffmann NA, Ochs SM et al (2012) Long-term in vivo imaging of fibrillar tau in the retina of P301S transgenic mice. PLoS One 7(12):e53547","journal-title":"PLoS One"},{"issue":"1","key":"9028_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/bpa.12070","volume":"24","author":"CY Ho","year":"2014","unstructured":"Ho CY, Troncoso JC, Knox D, Stark W, Eberhart CG (2014) Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer\u2019s and Parkinson\u2019s disease patients. Brain Pathol 24(1):25\u201332","journal-title":"Brain Pathol"},{"key":"9028_CR19","first-page":"267","volume":"8","author":"J Jiang","year":"2016","unstructured":"Jiang J, Wang H, Li W, Cao X, Li C (2016) Amyloid plaques in retina for diagnosis in Alzheimer\u2019s patients: a meta-analysis. Front Aging Neurosci 8:267","journal-title":"Front Aging Neurosci"},{"issue":"8","key":"9028_CR20","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1056\/NEJM198608213150804","volume":"315","author":"DR Hinton","year":"1986","unstructured":"Hinton DR, Sadun AA, Blanks JC, Miller CA (1986) Optic-nerve degeneration in Alzheimer\u2019s disease. N Engl J Med 315(8):485\u2013487","journal-title":"N Engl J Med"},{"issue":"1","key":"9028_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/NEN.0b013e31820376cc","volume":"70","author":"F Leger","year":"2011","unstructured":"Leger F, Fernagut PO, Canron MH et al (2011) Protein aggregation in the aging retina. J Neuropathol Exp Neurol 70(1):63\u201368","journal-title":"J Neuropathol Exp Neurol"},{"key":"9028_CR22","doi-asserted-by":"crossref","unstructured":"Ong SS, Doraiswamy PM, Lad EM (2018) Controversies and future directions of ocular biomarkers in Alzheimer disease. JAMA Neurol","DOI":"10.1001\/jamaneurol.2018.0602"},{"issue":"1","key":"9028_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0161-6420(90)32621-0","volume":"97","author":"AA Sadun","year":"1990","unstructured":"Sadun AA, Bassi CJ (1990) Optic nerve damage in Alzheimer\u2019s disease. Ophthalmology 97(1):9\u201317","journal-title":"Ophthalmology"},{"issue":"2","key":"9028_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/archopht.1991.01080020045040","volume":"109","author":"CS Tsai","year":"1991","unstructured":"Tsai CS, Ritch R, Schwartz B et al (1991) Optic nerve head and nerve fiber layer in Alzheimer\u2019s disease. Arch Ophthalmol 109(2):199\u2013204","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"9028_CR25","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ana.410330305","volume":"33","author":"CA Curcio","year":"1993","unstructured":"Curcio CA, Drucker DN (1993) Retinal ganglion cells in Alzheimer\u2019s disease and aging. Ann Neurol 33(3):248\u2013257","journal-title":"Ann Neurol"},{"issue":"6","key":"9028_CR26","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1136\/bjo.79.6.596","volume":"79","author":"DC Davies","year":"1995","unstructured":"Davies DC, McCoubrie P, McDonald B, Jobst KA (1995) Myelinated axon number in the optic nerve is unaffected by Alzheimer\u2019s disease. Br J Ophthalmol 79(6):596\u2013600","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"9028_CR27","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1600-0420.1996.tb00090.x","volume":"74","author":"TR Hedges 3rd","year":"1996","unstructured":"Hedges TR, 3rd, Perez Galves R, Speigelman D, Barbas NR, Peli E, Yardley CJ (1996) Retinal nerve fiber layer abnormalities in Alzheimer\u2019s disease. Acta Ophthalmol Scand 74(3):271\u2013275","journal-title":"Acta Ophthalmol Scand"},{"issue":"5","key":"9028_CR28","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1167\/iovs.06-1029","volume":"48","author":"F Berisha","year":"2007","unstructured":"Berisha F, Feke GT, Trempe CL, McMeel JW, Schepens CL (2007) Retinal abnormalities in early Alzheimer\u2019s disease. Invest Ophthalmol Vis Sci 48(5):2285\u20132289","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"9028_CR29","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.clineuro.2011.02.014","volume":"113","author":"A Kesler","year":"2011","unstructured":"Kesler A, Vakhapova V, Korczyn AD, Naftaliev E, Neudorfer M (2011) Retinal thickness in patients with mild cognitive impairment and Alzheimer\u2019s disease. Clin Neurol Neurosurg 113(7):523\u2013526","journal-title":"Clin Neurol Neurosurg"},{"key":"9028_CR30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12883-015-0268-6","volume":"15","author":"D Liu","year":"2015","unstructured":"Liu D, Zhang L, Li Z et al (2015) Thinner changes of the retinal nerve fiber layer in patients with mild cognitive impairment and Alzheimer\u2019s disease. BMC Neurol 15:14","journal-title":"BMC Neurol"},{"issue":"11","key":"9028_CR31","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1097\/00006324-199611000-00001","volume":"73","author":"RA Armstrong","year":"1996","unstructured":"Armstrong RA (1996) Visual field defects in Alzheimer\u2019s disease patients may reflect differential pathology in the primary visual cortex. Optom Vis Sci 73(11):677\u2013682","journal-title":"Optom Vis Sci"},{"issue":"1","key":"9028_CR32","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.neulet.2010.06.006","volume":"480","author":"Y Lu","year":"2010","unstructured":"Lu Y, Li Z, Zhang X et al (2010) Retinal nerve fiber layer structure abnormalities in early Alzheimer\u2019s disease: evidence in optical coherence tomography. Neurosci Lett 480(1):69\u201372","journal-title":"Neurosci Lett"},{"issue":"2","key":"9028_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.neulet.2007.02.090","volume":"420","author":"C Paquet","year":"2007","unstructured":"Paquet C, Boissonnot M, Roger F, Dighiero P, Gil R, Hugon J (2007) Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer\u2019s disease. Neurosci Lett 420(2):97\u201399","journal-title":"Neurosci Lett"},{"issue":"10","key":"9028_CR34","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1016\/S1388-2457(01)00620-4","volume":"112","author":"V Parisi","year":"2001","unstructured":"Parisi V, Restuccia R, Fattapposta F, Mina C, Bucci MG, Pierelli F (2001) Morphological and functional retinal impairment in Alzheimer\u2019s disease patients. Clin Neurophysiol 112(10):1860\u20131867","journal-title":"Clin Neurophysiol"},{"issue":"8","key":"9028_CR35","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1007\/s00415-014-7374-z","volume":"261","author":"FJ Ascaso","year":"2014","unstructured":"Ascaso FJ, Cruz N, Modrego PJ et al (2014) Retinal alterations in mild cognitive impairment and Alzheimer\u2019s disease: an optical coherence tomography study. J Neurol 261(8):1522\u20131530","journal-title":"J Neurol"},{"issue":"9","key":"9028_CR36","doi-asserted-by":"publisher","first-page":"5953","DOI":"10.1167\/iovs.13-12046","volume":"54","author":"E Marziani","year":"2013","unstructured":"Marziani E, Pomati S, Ramolfo P et al (2013) Evaluation of retinal nerve fiber layer and ganglion cell layer thickness in Alzheimer\u2019s disease using spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci 54(9):5953\u20135958","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"9028_CR37","first-page":"401","volume":"5","author":"XF He","year":"2012","unstructured":"He XF, Liu YT, Peng C, Zhang F, Zhuang S, Zhang JS (2012) Optical coherence tomograpy assessed retinal nerve fiber layer thickness in patients with Alzheimer\u2019s disease: a meta-analysis. Int J Ophthal 5(3):401\u2013405","journal-title":"Int J Ophthal"},{"key":"9028_CR38","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.dadm.2016.07.004","volume":"4","author":"B Knoll","year":"2016","unstructured":"Knoll B, Simonett J, Volpe NJ et al (2016) Retinal nerve fiber layer thickness in amnestic mild cognitive impairment: case\u2013control study and meta-analysis. Alzheimers Dement (Amst) 4:85\u201393","journal-title":"Alzheimers Dement (Amst)"},{"key":"9028_CR39","doi-asserted-by":"crossref","unstructured":"Lad EM, Mukherjee D, Stinnett SS et al (2018) Evaluation of inner retinal layers as biomarkers in mild cognitive impairment to moderate Alzheimer\u2019s disease. Plos One 13(2)","DOI":"10.1371\/journal.pone.0192646"},{"key":"9028_CR40","doi-asserted-by":"publisher","first-page":"636548","DOI":"10.1155\/2015\/636548","volume":"2015","author":"E Salobrar-Garcia","year":"2015","unstructured":"Salobrar-Garcia E, Hoyas I, Leal M et al (2015) Analysis of retinal peripapillary segmentation in early Alzheimer\u2019s disease patients. Biomed Res Int 2015:636548","journal-title":"Biomed Res Int"},{"issue":"7","key":"9028_CR41","doi-asserted-by":"publisher","first-page":"e581","DOI":"10.1111\/aos.12374","volume":"92","author":"MP Bambo","year":"2014","unstructured":"Bambo MP, Garcia-Martin E, Pinilla J et al (2014) Detection of retinal nerve fiber layer degeneration in patients with Alzheimer\u2019s disease using optical coherence tomography: searching new biomarkers. Acta Ophthalmol 92(7):e581\u2013e582","journal-title":"Acta Ophthalmol"},{"key":"9028_CR42","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ana.23926","volume":"74","author":"C Helmer","year":"2013","unstructured":"Helmer C, Malet F, Rougier M et al (2013) Is there a link between open-angle glaucoma and dementia? The three-city-alienor cohort. Ann Neurol 74:171\u2013179","journal-title":"Ann Neurol"},{"issue":"1","key":"9028_CR43","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0002-9394(01)01196-5","volume":"133","author":"AU Bayer","year":"2002","unstructured":"Bayer AU, Keller ON, Ferrari F, Maag KP (2002) Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer\u2019s disease and Parkinson\u2019s disease. Am J Ophthalmol 133(1):135\u2013137","journal-title":"Am J Ophthalmol"},{"key":"9028_CR44","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.2147\/OPTH.S69534","volume":"8","author":"AG Tsilis","year":"2014","unstructured":"Tsilis AG, Tsilidis KK, Pelidou S, Kitsos G (2014) Systematic review of the association between Alzheimer\u2019s disease and chronic glaucoma. Clin Ophthalmol 8:2095\u20132104","journal-title":"Clin Ophthalmol"},{"key":"9028_CR45","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3233\/JAD-140507","volume":"42","author":"JM Nolan","year":"2014","unstructured":"Nolan JM, Loskutova E, Howard AN et al (2014) Macular pigment, visual function, and macular disease among subjects with Alzheimer\u2019s disease: an exploratory study. J Alzheimer\u2019s Dis 42:1191\u20131202","journal-title":"J Alzheimer\u2019s Dis"},{"key":"9028_CR46","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3233\/JAD-132039","volume":"40","author":"M Gharbiya","year":"2014","unstructured":"Gharbiya M, Trebbastoni A, Parisi F et al (2014) Choroidal thinning as a new finding in Alzheimer\u2019s disease: evidence from enhanced depth imaging spectral domain optical coherence tomography. J Alzheimer\u2019s Dis 40:907\u2013917","journal-title":"J Alzheimer\u2019s Dis"},{"key":"9028_CR47","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.neulet.2014.10.010","volume":"584","author":"YT Ong","year":"2015","unstructured":"Ong YT, Hilal S, Cheung CY et al (2015) Retinal neurodegeneration on optical coherence tomography and cerebral atrophy. Neurosci Lett 584:12\u201316","journal-title":"Neurosci Lett"},{"key":"9028_CR48","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nrneurol.2012.227","volume":"9","author":"A London","year":"2013","unstructured":"London A, Benhar I, Schwartz M (2013) The retina as a window to the brain\u2014from eye research to CNS disorders. Nat Rev Neurol 9:44\u201353","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"9028_CR49","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/nrn3680","volume":"15","author":"L Conforti","year":"2014","unstructured":"Conforti L, Gilley J, Coleman MP (2014) Wallerian degeneration: an emerging axon death pathway linking injury and disease. Nat Rev Neurosci 15(6):394\u2013409","journal-title":"Nat Rev Neurosci"},{"issue":"9","key":"9028_CR50","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s00417-009-1060-3","volume":"247","author":"RM Dutescu","year":"2009","unstructured":"Dutescu RM, Li QX, Crowston J, Masters CL, Baird PN, Culvenor JG (2009) Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer\u2019s disease. Graefes Arch Clin Exp Ophthalmol 247(9):1213\u20131221","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"18","key":"9028_CR51","doi-asserted-by":"publisher","first-page":"11830","DOI":"10.1073\/pnas.192203399","volume":"99","author":"LV Johnson","year":"2002","unstructured":"Johnson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ, Anderson DH (2002) The Alzheimer\u2019s A beta-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci USA 99(18):11830\u201311835","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"9028_CR52","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/eye.2015.100","volume":"29","author":"JA Ratnayaka","year":"2015","unstructured":"Ratnayaka JA, Serpell LC, Lotery AJ (2015) Dementia of the eye: the role of amyloid beta in retinal degeneration. Eye (Lond) 29(8):1013\u20131026","journal-title":"Eye (Lond)"},{"issue":"2","key":"9028_CR53","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.exer.2003.10.011","volume":"78","author":"DH Anderson","year":"2004","unstructured":"Anderson DH, Talaga KC, Rivest AJ, Barron E, Hageman GS, Johnson LV (2004) Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. Exp Eye Res 78(2):243\u2013256","journal-title":"Exp Eye Res"},{"issue":"2","key":"9028_CR54","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1172\/JCI25843","volume":"116","author":"V Luibl","year":"2006","unstructured":"Luibl V, Isas JM, Kayed R, Glabe CG, Langen R, Chen J (2006) Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J Clin Invest 116(2):378\u2013385","journal-title":"J Clin Invest"},{"issue":"2","key":"9028_CR55","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1167\/iovs.09-3622","volume":"51","author":"KH Kurji","year":"2010","unstructured":"Kurji KH, Cui JZ, Lin T et al (2010) Microarray analysis identifies changes in inflammatory gene expression in response to amyloid-beta stimulation of cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 51(2):1151\u20131163","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"9028_CR56","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s10753-011-9379-4","volume":"35","author":"XC Liu","year":"2012","unstructured":"Liu XC, Liu XF, Jian CX, Li CJ, He SZ (2012) IL-33 is induced by amyloid-beta stimulation and regulates inflammatory cytokine production in retinal pigment epithelium cells. Inflammation 35(2):776\u2013784","journal-title":"Inflammation"},{"key":"9028_CR57","doi-asserted-by":"crossref","unstructured":"Frost S, Guymer R, Aung KZ et al (2016) Alzheimer\u2019s disease and the early signs of age-related macular degeneration. Curr Alzheimer Res","DOI":"10.2174\/1567205013666160603003800"},{"key":"9028_CR58","first-page":"184","volume":"9","author":"T Dentchev","year":"2003","unstructured":"Dentchev T, Milam AH, Lee VM, Trojanowski JQ, Dunaief JL (2003) Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. Mol Vis 9:184\u2013190","journal-title":"Mol Vis"},{"issue":"1","key":"9028_CR59","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.bbrc.2012.05.085","volume":"423","author":"J Wang","year":"2012","unstructured":"Wang J, Ohno-Matsui K, Morita I (2012) Elevated amyloid beta production in senescent retinal pigment epithelium, a possible mechanism of subretinal deposition of amyloid beta in age-related macular degeneration. Biochem Biophys Res Commun 423(1):73\u201378","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"9028_CR60","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1172\/JCI24635","volume":"115","author":"T Yoshida","year":"2005","unstructured":"Yoshida T, Ohno-Matsui K, Ichinose S et al (2005) The potential role of amyloid beta in the pathogenesis of age-related macular degeneration. J Clin Invest 115(10):2793\u20132800","journal-title":"J Clin Invest"},{"issue":"2","key":"9028_CR61","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1167\/iovs.08-2514","volume":"50","author":"JM Seddon","year":"2009","unstructured":"Seddon JM, Reynolds R, Rosner B (2009) Peripheral retinal drusen and reticular pigment: association with CFHY402H and CFHrs1410996 genotypes in family and twin studies. Invest Ophthalmol Vis Sci 50(2):586\u2013591","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"9028_CR62","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1001\/archopht.124.4.537","volume":"124","author":"TE Clemons","year":"2006","unstructured":"Clemons TE, Rankin MW, McBee WL, Age-Related Eye Disease Study Research G (2006) Cognitive impairment in the age-related eye disease study: AREDS report no. 16. Arch Ophthalmol 124(4):537\u2013543","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"9028_CR63","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1016\/j.ophtha.2012.04.026","volume":"119","author":"SJ Woo","year":"2012","unstructured":"Woo SJ, Park KH, Ahn J et al (2012) Cognitive impairment in age-related macular degeneration and geographic atrophy. Ophthalmology 119(10):2094\u20132101","journal-title":"Ophthalmology"},{"key":"9028_CR64","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1016\/j.ophtha.2015.07.033","volume":"122","author":"D Tsai","year":"2015","unstructured":"Tsai D, Chen S, Huang C, Yuan M, Leu H (2015) Age-related macular degeneration and risk of degenerative dementia among the elderly in Taiwan. Ophthalmology 122:2327\u20132335","journal-title":"Ophthalmology"},{"issue":"7","key":"9028_CR65","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/archophthalmol.2012.152","volume":"130","author":"SY Ong","year":"2012","unstructured":"Ong SY, Cheung CY, Li X et al (2012) Visual impairment, age-related eye diseases, and cognitive function: the Singapore Malay Eye study. Arch Ophthalmol 130(7):895\u2013900","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"9028_CR66","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jamaophthalmol.2013.5696","volume":"132","author":"TD Keenan","year":"2014","unstructured":"Keenan TD, Goldacre R, Goldacre MJ (2014) Associations between age-related macular degeneration, Alzheimer disease and dementia: record linkage study of hospital admissions. JAMA Ophthalmol 132(1):63\u201368","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"9028_CR67","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1177\/1533317513517032","volume":"29","author":"L Rozzini","year":"2014","unstructured":"Rozzini L, Riva M, Ghilardi N et al (2014) Cognitive dysfunction and age-related macular degeneration. Am J Alzheimers Dis Other Demen 29(3):256\u2013262","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"9365","key":"9028_CR68","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/S0140-6736(03)12981-9","volume":"361","author":"LE Goldstein","year":"2003","unstructured":"Goldstein LE, Muffat JA, Cherny RA et al (2003) Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer\u2019s disease. Lancet 361(9365):1258\u20131265","journal-title":"Lancet"},{"issue":"5","key":"9028_CR69","doi-asserted-by":"publisher","first-page":"e10659","DOI":"10.1371\/journal.pone.0010659","volume":"5","author":"JA Moncaster","year":"2010","unstructured":"Moncaster JA, Pineda R, Moir RD et al (2010) Alzheimer\u2019s disease amyloid-beta links lens and brain pathology in Down syndrome. PLoS One 5(5):e10659","journal-title":"PLoS One"},{"issue":"2","key":"9028_CR70","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.freeradbiomed.2004.10.023","volume":"38","author":"S Melov","year":"2005","unstructured":"Melov S, Wolf N, Strozyk D, Doctrow SR, Bush AI (2005) Mice transgenic for Alzheimer disease beta-amyloid develop lens cataracts that are rescued by antioxidant treatment. Free Radic Biol Med 38(2):258\u2013261","journal-title":"Free Radic Biol Med"},{"key":"9028_CR71","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.exer.2012.10.012","volume":"106","author":"R Michael","year":"2013","unstructured":"Michael R, Rosandic J, Montenegro GA et al (2013) Absence of beta-amyloid in cortical cataracts of donors with and without Alzheimer\u2019s disease. Exp Eye Res 106:5\u201313","journal-title":"Exp Eye Res"},{"key":"9028_CR72","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.exer.2015.03.010","volume":"140","author":"L Bei","year":"2015","unstructured":"Bei L, Shui YB, Bai F, Nelson SK, Van Stavern GP, Beebe DC (2015) A test of lens opacity as an indicator of preclinical Alzheimer disease. Exp Eye Res 140:117\u2013123","journal-title":"Exp Eye Res"},{"issue":"8","key":"9028_CR73","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1177\/1533317513520214","volume":"30","author":"C Kerbage","year":"2015","unstructured":"Kerbage C, Sadowsky CH, Tariot PN et al (2015) Detection of amyloid beta signature in the lens and its correlation in the brain to aid in the diagnosis of Alzheimer\u2019s disease. Am J Alzheimers Dis Other Demen 30(8):738\u2013745","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"2","key":"9028_CR74","first-page":"1008","volume":"1","author":"CH Sadowsky","year":"2014","unstructured":"Sadowsky CH, Kerbage C, Tariot PN et al (2014) Diagnosis of Alzheimer\u2019s disease through the eye and its correlation with cognitive tests and brain imaging. JSM Alzheimer\u2019s Dis Relat Dementai 1(2):1008","journal-title":"JSM Alzheimer\u2019s Dis Relat Dementai"},{"issue":"2","key":"9028_CR75","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s13167-010-0024-3","volume":"1","author":"I Grossman","year":"2010","unstructured":"Grossman I, Lutz MW, Crenshaw DG, Saunders AM, Burns DK, Roses AD (2010) Alzheimer\u2019s disease: diagnostics, prognostics and the road to prevention. EPMA J 1(2):293\u2013303","journal-title":"EPMA J"},{"key":"9028_CR76","first-page":"786494","volume":"2012","author":"M Parnell","year":"2012","unstructured":"Parnell M, Guo L, Abdi M, Cordeiro MF (2012) Ocular manifestations of Alzheimer\u2019s disease in animal models. Int J Alzheimers Dis 2012:786494","journal-title":"Int J Alzheimers Dis"},{"issue":"1","key":"9028_CR77","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S0002-9394(14)74985-2","volume":"100","author":"DG Cogan","year":"1985","unstructured":"Cogan DG (1985) Visual disturbances with focal progressive dementing disease. Am J Ophthalmol 100(1):68\u201372","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"9028_CR78","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/ana.410290110","volume":"29","author":"A Cronin-Golomb","year":"1991","unstructured":"Cronin-Golomb A, Corkin S, Rizzo JF, Cohen J, Growdon JH, Banks KS (1991) Visual dysfunction in Alzheimer\u2019s disease: relation to normal aging. Ann Neurol 29(1):41\u201352","journal-title":"Ann Neurol"},{"issue":"4","key":"9028_CR79","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/ageing\/32.4.422","volume":"32","author":"M Pache","year":"2003","unstructured":"Pache M, Smeets CH, Gasio PF et al (2003) Colour vision deficiencies in Alzheimer\u2019s disease. Age Ageing 32(4):422\u2013426","journal-title":"Age Ageing"},{"issue":"2","key":"9028_CR80","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/sj\/eye\/6700037","volume":"16","author":"KW Whittaker","year":"2002","unstructured":"Whittaker KW, Burdon MA, Shah P (2002) Visual field loss and Alzheimer\u2019s disease. Eye (Lond) 16(2):206\u2013208","journal-title":"Eye (Lond)"},{"issue":"2","key":"9028_CR81","doi-asserted-by":"publisher","first-page":"P52","DOI":"10.1093\/geronj\/49.2.P52","volume":"49","author":"GC Gilmore","year":"1994","unstructured":"Gilmore GC, Wenk HE, Naylor LA, Koss E (1994) Motion perception and Alzheimer\u2019s disease. J Gerontol 49(2):P52\u2013P57","journal-title":"J Gerontol"},{"issue":"1\u20134","key":"9028_CR82","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1159\/000335154","volume":"10","author":"Y Koronyo","year":"2012","unstructured":"Koronyo Y, Salumbides BC, Black KL, Koronyo-Hamaoui M (2012) Alzheimer\u2019s disease in the retina: imaging retinal abeta plaques for early diagnosis and therapy assessment. Neurodegener Dis 10(1\u20134):285\u2013293","journal-title":"Neurodegener Dis"},{"issue":"2","key":"9028_CR83","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10633-010-9238-x","volume":"121","author":"K Krasodomska","year":"2010","unstructured":"Krasodomska K, Lubinski W, Potemkowski A, Honczarenko K (2010) Pattern electroretinogram (PERG) and pattern visual evoked potential (PVEP) in the early stages of Alzheimer\u2019s disease. Doc Ophthalmol 121(2):111\u2013121","journal-title":"Doc Ophthalmol"},{"issue":"4","key":"9028_CR84","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3233\/JAD-2011-101908","volume":"24","author":"K Kaarniranta","year":"2011","unstructured":"Kaarniranta K, Salminen A, Haapasalo A, Soininen H, Hiltunen M (2011) Age-related macular degeneration (AMD): Alzheimer\u2019s disease in the eye? J Alzheimers Dis 24(4):615\u2013631","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"9028_CR85","first-page":"6683","volume":"52","author":"CW Ritchie","year":"2011","unstructured":"Ritchie CW, Peto T, Barzegar-Befroei N et al (2011) Peripheral retinal drusen as a potential surrogate marker for Alzheimer\u2019s dementia: a pilot study using ultra-wide angle imaging. Invest Ophthalmol Vis Sci 52(6):6683-","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"9028_CR86","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000487053","volume":"59","author":"L Csincsik","year":"2018","unstructured":"Csincsik L, MacGillivray TJ, Flynn E et al (2018) Peripheral retinal imaging biomarkers for Alzheimer\u2019s disease: a pilot study. Ophthalmic Res 59(4):182\u2013192","journal-title":"Ophthalmic Res"},{"issue":"1","key":"9028_CR87","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1364\/BOE.8.000016","volume":"8","author":"J Polans","year":"2017","unstructured":"Polans J, Keller B, Carrasco-Zevallos OM et al (2017) Wide-field retinal optical coherence tomography with wavefront sensorless adaptive optics for enhanced imaging of targeted regions. Biomed Opt Express 8(1):16\u201337","journal-title":"Biomed Opt Express"},{"issue":"1","key":"9028_CR88","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1364\/OL.42.000017","volume":"42","author":"J Polans","year":"2017","unstructured":"Polans J, Cunefare D, Cole E et al (2017) Enhanced visualization of peripheral retinal vasculature with wavefront sensorless adaptive optics optical coherence tomography angiography in diabetic patients. Opt Lett 42(1):17\u201320","journal-title":"Opt Lett"},{"key":"9028_CR89","doi-asserted-by":"crossref","unstructured":"Baumann B, W\u00f6hrer A, Ricken G, Pircher M, Kovacs GG, Hitzenberger CK (2016) Polarization properties of amyloid-beta plaques in Alzheimer\u2019s disease (Conference Presentation), p 96900M-M-1","DOI":"10.1117\/12.2212841"},{"issue":"7","key":"9028_CR90","doi-asserted-by":"publisher","first-page":"P319","DOI":"10.1016\/j.jalz.2016.06.577","volume":"12","author":"MCW Campbell","year":"2016","unstructured":"Campbell MCW, Kisilak ML, DeVries D et al (2016) Amyloid as a biomarker of Alzheimer\u2019s disease in post-mortem retinas in human and dog models of Alzheimer\u2019s disease. Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc 12(7):P319\u2013P320","journal-title":"Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc"},{"issue":"4","key":"9028_CR91","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1364\/BOE.7.001400","volume":"7","author":"S Kim","year":"2016","unstructured":"Kim S, Heflin S, Kresty LA et al (2016) Analyzing spatial correlations in tissue using angle-resolved low coherence interferometry measurements guided by co-located optical coherence tomography. Biomed Opt Express 7(4):1400\u20131414","journal-title":"Biomed Opt Express"},{"key":"9028_CR92","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jalz.2014.04.341","volume":"10","author":"S Frost","year":"2014","unstructured":"Frost S, Kanagasingam Y, Macaulay L (2014) Retinal amyloid fluorescence imaging predicts cerebral amyloid burden and Alzheimer\u2019s disease (oral presentation). Alzheimers Dement 10:234\u2013235","journal-title":"Alzheimers Dement"},{"issue":"6740","key":"9028_CR93","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/22124","volume":"400","author":"D Schenk","year":"1999","unstructured":"Schenk D, Barbour R, Dunn W et al (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400(6740):173\u2013177","journal-title":"Nature"},{"issue":"1","key":"9028_CR94","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","volume":"61","author":"JM Orgogozo","year":"2003","unstructured":"Orgogozo JM, Gilman S, Dartigues JF et al (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61(1):46\u201354","journal-title":"Neurology"},{"issue":"9634","key":"9028_CR95","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","volume":"372","author":"C Holmes","year":"2008","unstructured":"Holmes C, Boche D, Wilkinson D et al (2008) Long-term effects of Abeta42 immunisation in Alzheimer\u2019s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372(9634):216\u2013223","journal-title":"Lancet"},{"issue":"1","key":"9028_CR96","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/npp.2011.211","volume":"37","author":"AV Savonenko","year":"2012","unstructured":"Savonenko AV, Melnikova T, Hiatt A et al (2012) Alzheimer\u2019s therapeutics: translation of preclinical science to clinical drug development. Neuropsychopharmacology 37(1):261\u2013277","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"9028_CR97","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nn842","volume":"5","author":"JC Dodart","year":"2002","unstructured":"Dodart JC, Bales KR, Gannon KS et al (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer\u2019s disease model. Nat Neurosci 5(5):452","journal-title":"Nat Neurosci"},{"issue":"4","key":"9028_CR98","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC et al (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med 370(4):322\u2013333","journal-title":"N Engl J Med"},{"issue":"4","key":"9028_CR99","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, Thomas RG, Farlow M et al (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med 370(4):311\u2013321","journal-title":"N Engl J Med"},{"issue":"4","key":"9028_CR100","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/nrneurol.2014.44","volume":"10","author":"YJ Wang","year":"2014","unstructured":"Wang YJ (2014) Alzheimer disease: lessons from immunotherapy for Alzheimer disease. Nat Rev Neurol 10(4):188\u2013189","journal-title":"Nat Rev Neurol"},{"issue":"18","key":"9028_CR101","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","volume":"378","author":"MF Egan","year":"2018","unstructured":"Egan MF, Kost J, Tariot PN et al (2018) Randomized trial of verubecestat for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med 378(18):1691\u20131703","journal-title":"N Engl J Med"},{"issue":"4","key":"9028_CR102","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1210951","volume":"369","author":"RS Doody","year":"2013","unstructured":"Doody RS, Raman R, Farlow M et al (2013) A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease. N Engl J Med 369(4):341\u2013350","journal-title":"N Engl J Med"},{"issue":"4","key":"9028_CR103","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.cell.2014.10.016","volume":"159","author":"B De Strooper","year":"2014","unstructured":"De Strooper B (2014) Lessons from a failed gamma-secretase Alzheimer trial. Cell 159(4):721\u2013726","journal-title":"Cell"},{"key":"9028_CR104","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.exger.2014.05.002","volume":"57","author":"J Cedernaes","year":"2014","unstructured":"Cedernaes J, Schioth HB, Benedict C (2014) Efficacy of antibody-based therapies to treat Alzheimer\u2019s disease: just a matter of timing? Exp Gerontol 57:104\u2013106","journal-title":"Exp Gerontol"},{"issue":"7618","key":"9028_CR105","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussiere T et al (2016) The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease. Nature 537(7618):50\u201356","journal-title":"Nature"},{"key":"9028_CR106","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/nrd.2016.281","volume":"16","author":"A Mullard","year":"2017","unstructured":"Mullard A (2017) Alzheimer amyloid hypothesis lives on. Nat Rev Drug Discov 16:3\u20135","journal-title":"Nat Rev Drug Discov"},{"issue":"28","key":"9028_CR107","doi-asserted-by":"publisher","first-page":"E279","DOI":"10.1073\/pnas.1100901108","volume":"108","author":"JD Ding","year":"2011","unstructured":"Ding JD, Johnson LV, Herrmann R et al (2011) Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. Proc Natl Acad Sci USA 108(28):E279\u2013E287","journal-title":"Proc Natl Acad Sci USA"},{"issue":"23","key":"9028_CR108","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1007\/s00018-014-1709-x","volume":"71","author":"G Malek","year":"2014","unstructured":"Malek G, Lad EM (2014) Emerging roles for nuclear receptors in the pathogenesis of age-related macular degeneration. Cell Mol Life Sci 71(23):4617\u20134636","journal-title":"Cell Mol Life Sci"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-9028-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-018-9028-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-018-9028-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T17:55:57Z","timestamp":1720547757000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-018-9028-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,28]]},"references-count":108,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["9028"],"URL":"https:\/\/doi.org\/10.1007\/s00415-018-9028-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,28]]},"assertion":[{"value":"1 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SSO receives research funding from the International Retinal Research Foundation. EML has received research grants from Alzheimer\u2019s Association, Duke Institute for Brain Sciences and the National Eye Institute. HEW has received research grants from the Veterans Affairs Medical Center, National Institute on Aging and Alzheimer\u2019s Association. SF has received research grants from the National Institute of Health and Duke University, and holds US patent 8811745 and 9299155. PMD has received advisory fees from Avid\/Lilly, Anthrotronix, Muses Labs, AstraZeneca, Cognoptix, Lundbeck\/Takeda, Piramal, Genomind, Sonexa, Targacept, NeuroPro, Neurocog Trials, Forum, Holmusk, and T3D Therapeutics; research grants (through Duke University) from Elan, Avid\/Lilly, Avanir, Neuronetrix, Forum, Alzheimer\u2019s Drug Discovery Foundation, USC, and ADCS\/UCSD; fees for lectures from Hintsa Performance, Crossings; and fees for developing educational materials from Physicians Postgraduate Press. PMD owns shares or options in Maxwell Health, Muses Labs, Anthrotronix, Evidation, and Adverse Events Inc (whose products are not discussed here), and has received travel funds from Pfizer and the World Economic Forum. ADP reports no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This articles does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}